Elixxer Ltd Asset Resilience Ratio
Elixxer Ltd asset resilience ratio. Elixxer Ltd (ELXR) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Elixxer Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Elixxer Ltd (2017–2023)
Asset resilience ratio of Elixxer Ltd from 2017 to 2023. This chart shows how Elixxer Ltd's Asset Resilience Ratio has changed over time. See ELXR FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Elixxer Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Elixxer Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Elixxer Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Elixxer Ltd Industry Peers by Asset Resilience Ratio
Compare Elixxer Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Elixxer Ltd Asset Resilience Ratio by Year (2017–2023)
Elixxer Ltd asset resilience ratio by year from 2017 to 2023. The table below shows the annual Asset Resilience Ratio data for Elixxer Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$2.81 Million ≈ $2.03 Million |
-- |
| 2022-12-31 | 44.82% | CA$2.41 Million ≈ $1.74 Million |
CA$5.37 Million ≈ $3.88 Million |
-34.09pp |
| 2021-12-31 | 78.91% | CA$13.28 Million ≈ $9.61 Million |
CA$16.84 Million ≈ $12.18 Million |
-- |
| 2020-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$20.81 Million ≈ $15.06 Million |
-- |
| 2018-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$20.74 Million ≈ $15.00 Million |
-- |
| 2017-12-31 | 24.65% | CA$677.24K ≈ $489.91K |
CA$2.75 Million ≈ $1.99 Million |
-- |
About Elixxer Ltd
Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cultivation, production, and/or sale of medical cannabis and cannabis-derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. was incorporated in 2004 and is based in Mon… Read more